Literature DB >> 16023309

Comparative routes of oxytocin administration in crated farrowing sows and its effects on fetal and postnatal asphyxia.

Daniel Mota-Rojas1, Ma Elena Trujillo, Julio Martínez, Ana Ma Rosales, Héctor Orozco, Ramiro Ramírez, Héctor Sumano, María Alonso-Spilsbury.   

Abstract

Oxytocin is used to induce and control parturition; nevertheless, an increase in uterine contractions decreases blood flow and gaseous exchange through the uterus predisposing to intra-partum mortality in pigs. The objective of the present study was to evaluate the effect of different oxytocin administration routes on myometrial activity, fetal intrauterine hypoxia and postnatal asphyxia in crated farrowing sows. Yorkshire x Landrace hybrid sows (n = 300), that were approaching the time of parturition, were randomly assigned into six groups. Each group included 50 sows, 10 for each of the parities from one to five. A 40-IU oxytocin dosage was administered by intramuscular (IM), or intravulvar (IVU) routes, or 20 IU was administered via intravenous (IV) route. Groups 1 (G1), 3 (G3) and 5 (G5) were administered 0.9% saline solution (NaCl) IM, IVU and IV, respectively, whereas groups 2 (G2), 4 (G4) and 6 (G6) were treated with oxytocin IM, IVU and IV, respectively. There was a significantly (P < 0.05) greater number of intra-partum stillbirths (IPS) for the oxytocin treatments, as compared with the control groups, especially with the IVU and IV routes; a lesser number of IPS and lesser IPS with broken umbilical cords was observed with the IM administration route. Oxytocin and control IV administration resulted in longer farrowing durations. Administration of IV-oxytocin resulted in a greater number (P < 0.05) of intrauterine distressed neonates compared with its corresponding control and interpreted through dips II, a fetal cardiac frequency deceleration which determines acute fetal suffering. Independent of the route of oxytocin administration, the treatments resulted in twice as many dips II compared with the respective control groups. The use of the cardiotocograph proved to be an excellent tool for establishing the oxytocin response dose in farrowing sows. A greater number of piglets born alive, which had undergone bradycardia, also showed severe acidosis and greater meconium staining in oxytocin-treated sows, indicating that the administration time (at birth of the first piglet) as well as the dosage used were not adequate treatment regimens in the present study. Further studies will be conducted to evaluate different dosages and oxytocin administration timing to determine the most desirable treatment regimen to increase myometrial contractibility without compromising fetal welfare and neonatal survival.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16023309     DOI: 10.1016/j.anireprosci.2005.04.012

Source DB:  PubMed          Journal:  Anim Reprod Sci        ISSN: 0378-4320            Impact factor:   2.145


  4 in total

1.  Comparative effects of dietary supplementations with sodium butyrate, medium-chain fatty acids, and n-3 polyunsaturated fatty acids in late pregnancy and lactation on the reproductive performance of sows and growth performance of suckling piglets.

Authors:  Jinchao Chen; Qingqing Xu; Yunxia Li; Zhiru Tang; Weizhong Sun; Xiangxin Zhang; Jiajing Sun; Zhihong Sun
Journal:  J Anim Sci       Date:  2019-10-03       Impact factor: 3.159

2.  Risk factors associated with stillbirth of piglets born from oxytocin-assisted parturitions.

Authors:  Nguyen Hoai Nam; Peerapol Sukon
Journal:  Vet World       Date:  2020-10-17

3.  Non-infectious risk factors for intrapartum stillbirth in a swine farm in the North of Vietnam.

Authors:  Nguyen Hoai Nam; Peerapol Sukon
Journal:  Vet World       Date:  2021-07-16

Review 4.  Defining the Effect of Oxytocin Use in Farrowing Sows on Stillbirth Rate: A Systematic Review with a Meta-Analysis.

Authors:  Sarah V Hill; Maria Del Rocio Amezcua; Eduardo S Ribeiro; Terri L O'Sullivan; Robert M Friendship
Journal:  Animals (Basel)       Date:  2022-07-13       Impact factor: 3.231

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.